Company Description
Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease.
Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised of mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.
The company’s lead candidate is FXR314, which is phase 2/3clinical trial for indication of inflammatory bowel disease with a clinical focus on ulcerative colitis; and completed phase 1 clinical trial for the indication of liver fibrosis with a clinical focus steatohepatitis.
Organovo Holdings, Inc. has research collaborations with Yale School of Medicine, Knight Cancer Institute at Oregon Health & Science University, and the University of Virginia for research of NovoGen Bioprinters.
The company was incorporated in 2007 and is headquartered in San Diego, California.
| Country | United States |
| Founded | 2007 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 20 |
| CEO | Keith E. Murphy |
Contact Details
Address: 11555 Sorrento Valley Road, Suite 100 San Diego, California 92121 United States | |
| Phone | 858-224-1000 |
| Website | organovo.com |
Stock Details
| Ticker Symbol | ONVO |
| Exchange | NASDAQ |
| Fiscal Year | April - March |
| Reporting Currency | USD |
| CIK Code | 0001497253 |
| CUSIP Number | 68620A203 |
| ISIN Number | US68620A2033 |
| Employer ID | 27-1488943 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Keith E. Murphy | Executive Chairman and Corporate Secretary |
| Thomas P. Hess CPA, MBA | President and Chief Financial Officer |
| Vaidehi Joshi | Director of Discovery Biology and Director |
| Dr. Curtis M. Tyree Ph.D. | Senior Vice President of Strategy and Business Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 25, 2024 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Oct 7, 2024 | ARS | Filing |
| Oct 7, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Oct 7, 2024 | DEF 14A | Other definitive proxy statements |
| Sep 18, 2024 | PRE 14A | Other preliminary proxy statements |
| Aug 9, 2024 | 8-K | Current Report |
| Aug 5, 2024 | 10-Q | Quarterly Report |
| Jul 26, 2024 | 10-K/A | [Amend] Annual report |
| Jul 24, 2024 | 8-K | Current Report |
| May 31, 2024 | 10-K | Annual Report |